The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.

Final guidance published today (Thursday 4 December 2025) conditionally recommends seven digital technologies that can support cardiac rehabilitation for adults with cardiovascular disease in the NHS.

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma TA1113 3 December 2025 3 December 2025 Talquetamab for treating relapsed and refractory ...

Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290] Medicines evaluation Not selected 12 December 2025 Cyclosporin eye drops for treating ...

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. There is a commercial access agreement ...

This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, ...

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...

Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults. This guidance updates and replaces ...

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) British National Formulary for Children (BNFC) Life sciences Library and knowledge services What ...

This guidance has been updated and replaced by NICE technology appraisal guidance 908 ...

Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. There is a simple discount patient ...

Decisions about updating our guidance are made by NICE’s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual. For information about ...